Network Immunology Inc. Reports Filing of New Intellectual Property
Network Immunology, a preclinical stage biotech company focused on novel treatments to prevent and treat automimmune conditions and cancer, files patent for HIV and organ transplantation technologies. On January 4th, 2011, Network Immunology Inc. filed provisional patent applications for it’s HIV vaccine and organ transplantation technologies. Both of these technologies have emerged from recent developments in Network Theory as applied to the immune system, and are closely related to each other at the level of the fundamental science. This was soon followed by a patent application for its MAB3 technology. On January 4th, 2012, the Company filed three Patent Convention Treaty applications, one for each of its technologies. Network Immunology Inc. is seeking private equity financing in order to develop these technologies as quickly as possible.